RxDoctor Payments Data

Kyle Fehlis, MD

Family Medicine · New Braunfels, TXNPI 1215167119

Payments from drug & device makers

$7,009in general payments, 2019–2025

Across 251 payments — averaging $27.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$694
  • AbbVie$682
  • Amgen$650
  • Amarin Pharma, Inc.$371
  • Teva Pharmaceuticals USA, Inc.$323
  • Pfizer$315
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$6,97399%
  • Education$361%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,009 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$69,498
Medicare patients
256
Services billed
1,084

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide57$58,937
Synjardy XrEmpagliflozin/Metformin Hcl67$54,157
TrulicityDulaglutide43$53,029
EliquisApixaban42$46,314
RybelsusSemaglutide36$42,928
Teriparatide21$40,925
OzempicSemaglutide20$29,879
Evenity (2 Syringes)Romosozumab-Aqqg12$29,081
Repatha SureclickEvolocumab25$26,145
XareltoRivaroxaban30$23,821
JardianceEmpagliflozin22$23,365
Bydureon BciseExenatide Microspheres28$23,188
MyrbetriqMirabegron37$22,340
ProliaDenosumab12$19,397
Trijardy XrEmpaglifloz/Linaglip/Metformin18$18,215

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimSynjardy Xr, Jardiance, Trijardy Xr, Stiolto Respimat, Tradjenta$146$112,122135 claims
Lilly USA, LLCMounjaro, Trulicity$257$111,966100 claims
Novo NordiskRybelsus, Ozempic$244$72,80756 claims
AmgenEvenity (2 Syringes), Prolia$650$48,47824 claims
PfizerEliquis$315$46,31442 claims
Alvogen IncTeriparatide$25$40,92521 claims
Johnson & JohnsonXarelto$694$23,82130 claims
Astellas Pharma US IncMyrbetriq$61$22,34037 claims
GSKTrelegy Ellipta$106$14,49019 claims
AstraZenecaBreztri Aerosphere$261$10,73115 claims
AbbVieSynthroid$682$2,39129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.

Other family medicine in New Braunfels

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →